Download PDF
TumorDiagnostik & Therapie 2014; 35(4): 194-196
DOI: 10.1055/s-0034-1369137
Schwerpunkt: Nierenzellkarzinom
Georg Thieme Verlag KG Stuttgart · New York

Übersicht – Möglichkeiten der molekularen Diagnostik von Nierenzelltumoren

K. Junker
Further Information

Publication History

Publication Date:
25 June 2014 (online)

Also available at
    Permissions and Reprints

Nierenzellkarzinome (NZK) haben einen Anteil von 3% an allen malignen Erkrankungen im Erwachsenenalter. Es ist heute klar belegt, dass die primär histologisch definierten Subtypen (klarzellig, papillär, chromophob, Onkozytom) aufgrund ihrer spezifischen differenten molekularen Veränderungen sowie der unterschiedlichen Prognose als eigenständige Tumorentitäten betrachtet werden müssen.

 

  • Literatur

  • 1 Sanjmyatav J, Hauke S, Gajda M et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Europ Urol 2013; 64: 689-691
    CrossrefPubMedGoogle Scholar
  • 2 Chyhrai A, Sanjmyatav J, Gajda M et al. Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. World J Urol 2010; 28: 269-274
    CrossrefPubMedGoogle Scholar
  • 3 Youssef YM, White NM, Grigull J et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Europ Urol 2011; 59: 721-730
    CrossrefPubMedGoogle Scholar
  • 4 Tolson J, Bogumil R, Brunst E et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004; 84: 845-856
    CrossrefPubMedGoogle Scholar
  • 5 Monzon FA, Alvarez K, Peterson L et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Path 2011; 24: 1470-1479
    CrossrefPubMedGoogle Scholar
  • 6 Klatte T, Rao PN, de Martino M et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27: 746-753
    CrossrefPubMedGoogle Scholar
  • 7 Sanjmyatav J, Junker K, Matthes S et al. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J Urol 2011; 186: 2078-2083
    CrossrefPubMedGoogle Scholar
  • 8 Heinzelmann J, Henning B, Sanjmyatav J et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011; 29: 367-373
    CrossrefPubMedGoogle Scholar
  • 9 Wu X, Weng L, Li X et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PloS one 2012; 7: e35661
    CrossrefPubMedGoogle Scholar
  • 10 Slaby O, Redova M, Poprach A et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chrom Canc 2012; 51: 707-716
    PubMedGoogle Scholar
  • 11 Hildebrandt MA, Gu J, Lin J et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728
    CrossrefPubMedGoogle Scholar
  • 12 Teixeira AL, Ferreira M, Silva J et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tum Biol 2013;
    PubMedGoogle Scholar
  • 13 Hauser S, Wulfken LM, Holdenrieder S et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3 p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidem 2012; 36: 391-394
    PubMedGoogle Scholar
  • 14 Redova M, Poprach A, Nekvindova J et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012; 10: 55
    CrossrefPubMedGoogle Scholar
  • 15 Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49
    CrossrefPubMedGoogle Scholar
  • 16 Hakimi AA, Ostrovnaya I Reva Bet al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013; 19: 3259-3267
    CrossrefPubMedGoogle Scholar
  • 17 Kapur P, Pena-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14: 159-167
    CrossrefPubMedGoogle Scholar
  • 18 Sato Y, Yoshizato T, Shiraishi Y et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Gen 2013; 45: 860-867
    CrossrefPubMedGoogle Scholar
  • 19 Klatte T, Seligson DB, LaRochelle J et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol 2009; 18: 894-900
    CrossrefPubMedGoogle Scholar
  • 20 Eichelberg C, Chun FK, Bedke J et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer 2013; 132: 2948-2955
    CrossrefPubMedGoogle Scholar
  • 21 Parker AS, Leibovich BC, Lohse CM et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115: 2092-2103 Ch. D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Gen Cancer 2007; 5: 379–385
    CrossrefPubMedGoogle Scholar
  • 22 Nishikawa M, Miyake H, Harada K et al. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol 2014; 31: 792
    CrossrefPubMedGoogle Scholar
  • 23 Prior C, Perez-Gracia JL et al. Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PloS one 2014; 9: e86263
    CrossrefPubMedGoogle Scholar
  • 24 Alqurashi N, Hashimi SM, Wei MQ. Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int L Mol Sci 2013; 14: 3874-3900
    PubMedGoogle Scholar
  • 25 Garcia-Donas J, Esteban E, Leandro-Garcia LJ et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143-1150
    CrossrefPubMedGoogle Scholar
  • 26 van der Veldt AA, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011; 17: 620-629
    CrossrefPubMedGoogle Scholar
  • 27 Xu CF, Bing NX, Ball HA et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011; 29: 2557-2564
    CrossrefPubMedGoogle Scholar
  • 28 Gamez-Pozo A, Anton-Aparicio LM, Bayona C et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012; 14: 1144-1152
    CrossrefPubMedGoogle Scholar